Study protocol: randomised controlled hybrid type 2 trial evaluating the scale-up of two arts interventions for postnatal depression and Parkinson’s disease

Tayana Soukup, Rachel E Davis, Maria Baldellou Lopez, Andy Healey, Carolina Estevao, Daisy Fancourt, Paola Dazzan, Carmine Pariante, Hannah Dye, Tim Osborn, Rebecca Bind, Kristi Sawyer, Lavinia Rebecchini, Katie Hazelgrove, Alexandra Burton, Manonnni Manoharan, Rosie Perkins, Aleksandra Podlewska, Ray Chaudhuri, Fleur Derbyshire-Fox, Alison Hartley, Anthony Woods, Nikki Crane, Ioannis Bakolis, Nick Sevdalis

ABSTRACT

Introduction Research on the benefits of ‘arts’ interventions to improve individuals’ physical, social and psychological well-being is growing, but evidence on implementation and scale-up into health and social care systems is lacking. This protocol reports the SHAPER-Implement programme (Scale-up of Health-Arts Programmes Effectiveness-Implementation Research), aimed at studying the impact, implementation and scale-up of: Melodies for Mums (M4M), a singing intervention for postnatal depression; and Dance for Parkinson’s (PD-Ballet) a dance intervention for Parkinson’s disease. We examine how they could be embedded in clinical pathways to ensure their longer-term sustainability.

Methods and analysis A randomised two-arm effectiveness-implementation hybrid type 2 trial design will be used across M4M/PD-Ballet. We will assess the implementation in both study arms (intervention vs control), and the cost-effectiveness of implementation. The design and measures, informed by literature and previous research by the study team, were refined through stakeholder engagement. Participants (400 in M4M; 160 in PD-Ballet) will be recruited to the intervention or control group (2:1 ratio). Further implementation data will be collected from stakeholders involved in referring to, delivering or supporting M4M/PD-Ballet (N=25–30 for each intervention).

A mixed-methods approach (surveys and semi-structured interviews) will be employed. ‘Acceptability’ (measured by the ‘Acceptability Intervention Measure’) is the primary implementation endpoint for M4M/PD-Ballet. Relationships between clinical and implementation outcomes, implementation strategies (eg, training) and outcomes will be explored using generalised linear mixed models. Qualitative data will assess factors affecting the acceptability, feasibility and appropriateness of M4M/PD-Ballet, implementation strategies and longer-term sustainability. Costs associated with implementation and future scale-up will be estimated.

Strengths and limitations of this study

► Scale-up of Health-Arts Programmes Effectiveness-Implementation Research—Implement is the largest known study of its kind, comprising multidisciplinary implementation and evaluation teams, with consistent stakeholder engagement embedded throughout.

► The study allows large-scale psychometric validation of newly developed implementation measures.

► Provides an example of how large-scale hybrid studies can be conducted within community settings using a synergistic methodology with broad applicability.

► Dance for Parkinson’s and Melodies for Mums will be trialled in specific geographic areas in England, further assessment of the interventions across England will be required to assess the wider benefit.

Ethics and dissemination SHAPER-PND (the M4M trial) and SHAPER-PD (the PD trial) are approved by the West London and GTAC (20/PR/0813) and the HRA and Health and Care Research Wales (REC Reference: 20/WA/0261) Research Ethics Committees. Study findings will be disseminated through scientific peer-reviewed journals and scientific conferences.

Trial registration numbers Both trials are registered with NIH US National Library of Medicine, ClinicalTrials.gov. The trial registration numbers, URLs of registry records, and dates of registration are: (1) PD-Ballet: URL: NCT04719468 (https://eure3.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNC104719468%3Term%3DNC104719468%26draw%3D2%26rank%3D1&data=0%7C01%7Crachelle.bakolis%40kcl.ac.uk%7C11a7c5142782437919f808d9031114497c3870c1f416034c16b83c742071654356%7C0%7C0%7C6375441942616) (date of registration: 22 Jan 2021). (2) Melodies for Mums: NCT04834622 (https://...
INTRODUCTION

The use of arts interventions (ie, ‘creative methods of expression such as drama, music and visual arts’) to improve health and social care outcomes and reduce service utilisation costs is an internationally growing area of research. In 2017, the UK’s All-Party Parliamentary Group on Arts, Health and Wellbeing published a report on the benefits of arts interventions, alongside ten stakeholder-led recommendations (from patients, health and social care professionals, artists, academics, charities, policy-makers and parliamentarians) on facilitating the implementation and scale-up of ‘arts’ into health and social care systems nationally. Two years on, the WHO’s scoping review of the global academic literature (2000–2019) identified over 900 publications, including 200 reviews, systematic reviews, meta-analyses and meta-syntheses covering over 3000 studies, and 700 additional studies. Taken the evidence collectively, arts interventions are an effective method to help treat a plethora of physical, social and psychological problems across the lifespan. Despite the promising evidence, progress on successfully embedding art interventions in health and social care systems has been slow. Presently, many ‘arts’ are delivered in small geographic or healthcare pockets, operating at the fringe of the care sector rather than receiving mainstream funding. While lack of sustainable funding, weak partnerships with commissioners and unclear referral pathways partly account for this, research is required to establish cost-effective, scalable solutions so that the full benefits to the wider population can be reached.

The current protocol reports the design and evaluation of the ‘Scale-up of Health-Arts Programmes Effectiveness-Implementation Research’ (SHAPER-Implement)—part of a larger programme (referred to as ‘SHAPER’) aimed at investigating ways to implement and deliver arts interventions at scale. We focus on two different health conditions: postnatal depression (PND) and Parkinson’s disease (PD). These represent a significant fiscal and public health burden and pose considerable affliction on the individuals affected (and, where applicable, their carers). While pharmacological treatments can be effective for controlling/alleviating symptoms, they are fraught with challenges: for PND, it is poor uptake and adherence, while for PD, it is overemphasis on treating the motor symptoms at the expense of non-motor functioning.

Melodies for Mums (M4M) (for mums with PD) and Dance for Parkinson’s (PD-Ballet) (for individuals with PD) are two approaches to symptom management, that have been piloted with promising results. Both have already been implemented across certain locations in London, UK, but are not being delivered at scale, thus only reach a fraction of eligible individuals.

We plan to scale-up M4M/PD-Ballet and examine how we can embed them into clinical pathways so that a greater number of individuals can benefit. Our ambition is to be as inclusive as possible, reaching out to individuals who may not be undergoing treatment for their condition (as well as those that are), and ultimately for Clinical Commissioning Groups (eg, the ‘payers’ in the National Health Service, UK) to commission the interventions so they can be delivered in a sustainable way beyond the end of our research.

The entire SHAPER programme centres on tripartite objectives. Due to the complexity of the study design, this protocol reports the implementation effectiveness evaluation (ie, the SHAPER-Implement programme) of M4M/PD-Ballet (objectives 2 and 3, described below). The clinical effectiveness evaluation (objective 1) is reported in parallel protocols.

Objective 1
To assess the clinical effectiveness of M4M/PD-Ballet—described in detail in the clinical protocols.

Objective 2
To examine the implementation effectiveness of M4M/PD-Ballet, including uptake, adoption, perceived acceptability, appropriateness, feasibility, fidelity, unintended consequences and sustainability, and the impact of established implementation strategies (eg, training in the delivery of M4M/PD-Ballet) on implementation effectiveness.

Objective 3
To assess implementation costs and cost effectiveness, including costs associated with implementing M4M/PD-Ballet into existing care pathways, health service, partner organisations and commissioning, costs to service users attending M4M/PD-Ballet vs the benefit in terms of quality-adjusted years of life lived, and the impact of M4M/PD-Ballet when delivered at scale, on the wider utilisation of healthcare and other services.

METHODS AND ANALYSIS

Design

SHAPER-Implement is a two-arm effectiveness-implementation hybrid type 2 trial of M4M/PD-Ballet. Randomisation will be single-blinded (assessments performed by a blinded rater) and in a 2:1 ratio. M4M participants will receive the singing programme (intervention) or be encouraged to attend non-music classes in the community or online (control). PD-Ballet participants will receive a dance programme (dance-based training and a post-session Tea-and-Biscuit social time) or follow the standard treatment per the local pathway (control) and attend the post-training ‘Tea-and-Biscuit’ gatherings via an online platform.

Table 1 describes how M4M/PD-Ballet meet the criteria proposed by Curran et al for a hybrid type 2 trial.
Contextual constraints meant it was not feasible to randomise the implementation side of the trial (ie, allocate participants to different implementation strategies): but we will examine the effectiveness of the implementation strategies used to deploy M4M/PD-Ballet.

**Setting**

SHAPER-Implement is a multisite, multidisciplinary, community-based study in London, UK. Funded by the Wellcome Trust, it is a collaboration between the Centre for Implementation Science, King’s College London; King’s Health Partners; the Department for Behavioural Science and Health and the Institute of Mental Health, University College London, and two award-winning arts organisations: Breathe Arts Health Research and English National Ballet (ENB). King’s holds a long-established commitment to embedding arts, health and well-being in education and research, and was the research partner for landmark publications in the area.

**Health conditions**

PND is a serious and the most common perinatal mental health condition, affecting 10%–20% of women in pregnancy and after birth. If left untreated the impact on women and their families can be devastating with symptoms including fatigue, anhedonia, insomnia and...
irritability and thoughts of suicide. Therapy (eg, cognitive-behavioural therapy) or medication can be prescribed to help treat PND but progress can be slow, may involve long wait times for treatment (for therapy) or prolonged use of medication—thus other options for symptom management need to be explored.

PD is one of the world’s fastest growing chronic neurodegenerative disorders, with those aged over 70 being particularly vulnerable. It affects over 145,000 people in the UK alone with prevalence rates expected to rise by around 18% between 2018 and 2025 (to over 168,000), and doubling by 2065. Symptoms relate to motor (eg, tremor, bradykinesia, freezing of gait) and non-motor (eg, sleep disturbance, drooling, cognitive decline) functioning. Currently, there is no cure for PD—and the disease has a progressive course. Pharmacological treatments can alleviate symptoms and improve quality of life but are largely aimed at addressing motor functioning, leaving the non-motor symptoms often unrecognised or under-treated. Alternative non-pharmacotherapies are necessary to slow down disease progression.

Interventions

Drawing from Curran et al’s ‘hybrid’ framework (see table 1) through an intensive 4-month stakeholder engagement with artists, researchers, clinicians and commissioners, we considered five elements critical to assessing the relevance of the interventions:

- **Suitability**: M4M/PD-Ballet address a need within the health sector—there are growing patient populations with the conditions and lack of effective current service provision.
- **Quality and face validity**: M4M/PD-Ballet are ‘high-quality’ interventions with carefully designed and tailored activities, developed in partnership between centres of academic excellence and renowned arts organisations.
- **Inclusivity**: M4M/PD-Ballet are ‘all-inclusive’. They have good uptake, not only with those already engaged in the arts. They also appear to ‘reach-out’ to individuals that are disengaged in other forms of treatment for PND/PD (eg, pharmacological approaches).
- **Effectiveness**: there is evidence to show M4M/PD-Ballet improves symptoms and quality of life and can achieve better adherence than pharmacological approaches.
- **Scalability**: M4M/PD-Ballet are not overly complex, thus have the potential to be scaled-up, embedded in clinical pathways and commissioned by the health sector.

M4M is delivered in partnership with Breathe Arts Health Research (https://breatheahr.org/melodies-forums/). A breathe-trained artist (the workshop leader) and support assistant deliver ten weekly singing sessions to a group of mums with PND and their babies. Classes start with welcome songs, followed by music activities, ranging from short vocal exercises and simple lullabies to longer songs that attendees learn gradually over the weeks. Songs can be relaxing, with mothers encouraged to hug/stroke their babies as they sing, or energetic, with mothers standing and moving with their babies. Instruments (eg, guitars and ukuleles) are used by the workshop leader, accompanied by simpler instruments for mothers/babies to use. Mothers are encouraged to write their own songs, developing lyrics together relating to their babies or experiences of motherhood. Recordings of the singing sessions are made available to attendees at the end.

M4M has been subject to a three-arm randomised controlled trial (RCT) of 134 mothers and a preliminary process evaluation. Significantly faster improvements in symptoms for mothers with moderate-severe PND (measured by the Edinburgh Postnatal Depression Scale (EPDS)), than mothers in usual care were observed. Levels of depression consistently declined—by week 6, 65% of mothers no longer had an EPDS ≥13 (ie, indicating no more than mild depression); increasing to 73% by week 10. Increase in the frequency of mothers singing to their babies outside the classes, perceived mother-infant closeness and a greater decrease in cortisol levels when compared with social play were also reported. The process evaluation showed that M4M reached the correct target demographic, was delivered with a high level of fidelity and programme satisfaction was high—88% of mothers agreed the classes were well tailored, and 100% would recommend M4M to another mother. Several challenges, however, were highlighted by mothers, workshop leaders and the project coordinator (eg, timing sessions with babies’ routines)—while this did not hinder the continuation of M4M, it nonetheless suggests that implementation of M4M could be improved.

**PD-Ballet** is based on the ENB’s pre-existing ‘Dance for Parkinson’ (DIP) programme (referred to as PD-Ballet for the SHAPER research) and delivered in partnership with the ENB (https://www.ballet.org.uk/project/dance-for-parkinsons/). Led by an ENB trained DIP Associate Artist and Associate Musician who deliver 12 weekly sessions to individuals with PD (carers/relatives can also attend), sessions comprise live music, dance and vocal exercises. Each session comprises 75 min of activity, followed by social time and refreshments (up to 1 hour) so that participants can get to know fellow attendees and form social networks. Content, inspired by the ENB’s classical and contemporary works, provides a framework for participants to explore narrative, themes, concepts and music to promote freedom of expression. A performance sequence is developed at the end of PD-Ballet, combining all elements of the programme. Dance material is adapted to be inclusive (catering for differing levels of mobility) so that everyone can participate fully. For PD-Ballet content will be further developed for the three distinct stages of motor advancement (mild/moderate/severe)—something which has not been done before within the existing DIP programme. Prior to the programme, individuals attend an introductory session with their assigned group and are given the opportunity...
to attend a ballet performance and a behind the scenes event.6,32

Initial testing of PD-Ballet in London, and its regional affiliated hub partners, has proven to be replicable, resulting in it being trialled and established in four other locations in the UK (Oxford, Cardiff, Ipswich and Liverpool). An independent evaluation led by the University of Roehampton (on scaling-up the programme, experiences and benefits of participation across 4 years and the effects on the body, daily activities and social participation) reported high levels of perceived value from an emotional, social and artistic perspective.29 Additionally, PD-Ballet can decrease social isolation and improve quality of life,22 with participants highly motivated and viewing PD-Ballet as an important part of their lives.27 Equally, while recent systematic reviews and studies on the effects of performing acts modalities (including dance and ballet) reported promising benefits on Parkinson’s symptoms29,30 very few RCTs have investigated the benefits of ‘dance’ in both motor and non-motor symptoms, pointing to the need for this research.

SHAPER-Implement will build on previous research—conducting a full RCT (for PD-Ballet), a follow-up RCT scaled to a larger number of mothers (for M4M), and a process evaluation and examination of the implementation and potential cost-effectiveness of delivery at scale (for both) (see table 2 for further details on M4M/PD-Ballet).

**Implementation and adaption: COVID-19 pandemic**

As a result of the first national lockdown in the UK on 23 March 2020 and the guidelines that followed, M4M/PD-Ballet were adapted to be delivered online and preliminary research into the feasibility of using an online platform is underway. While the plan moving forward (ie, when the trials begin) will be to deliver PD-Ballet and M4M face-face, this will be continually reviewed based on the government guidelines on COVID-19 at the time, and the switch to remote delivery of the programmes will be made if necessary.

**Theoretical underpinning**

The Medical Research Council’s (MRC) framework for evaluating complex interventions47 48 informed the study design for intervention development, implementation and evaluation processes.

The ‘Implementation Science Research Development’ tool,46 allowed us to operationalise the MRC guidance into the overall design of SHAPER-Implement, along with the research team’s knowledge and experience of conducting hybrid trials.50 We also tailored intervention delivery using the COM-B model51 by considering factors that could affect individuals’ capability, opportunity and motivation to engage with M4M/PD-Ballet.

| Table 2 Overview of the structure and delivery of Melodies for Mums and PD-Ballet interventions |
|---------------------------------------------------------------|
| **Programme structure and delivery** | **Melodies for Mums** | **PD-Ballet** |
| Arts partner | Breathe Arts Health Research | English National Ballet |
| Targeted health condition | Postnatal depression | Parkinson’s disease |
| Setting | Community children’s centres OR online (depending on COVID-19 guidelines) | Community dance studios OR online (depending on COVID-19 guidelines) |
| Delivery structure | A weekly 1-hour group session over 10 weeks | A weekly 2 hours 15 min 12-group session over 12 weeks |
| N of intervention cycles | 10 cycles, with a morning and afternoon cycle held across 5 separate10 weekly periods | 3 cycles (stratified by motor advancement—mild/moderate/severe) |
| N of participants per cohort | 12–15 | 30–35 |
| Total N of participants in the intervention | 270 mums (plus their respective babies) | 107 individuals with Parkinson’s* |
| Follow-ups (as related to the delivery of sessions) | No follow-up | No follow-up |
| Artists per session | 2 (1 artist, 1 assistant) | 4 (2 associate dance artists/2 associate musicians), plus 1 artist-in-training |
| Total N of participants in the control | N=130 mums | N=53 |

*The three cohorts differ in the severity of Parkinson’s symptoms: mild, moderate and severe
†The 2 days training is required for each stage of motor advancement so the trainer would need to attend three 2 day training sessions if they running programmes for all three groups of motor advancement (mild/moderate/severe).
N, number; PD-Ballet, Dance for Parkinson’s.
compendium of implementation strategies will guide the identification of implementation strategies that could overcome some of the factors affecting implementation.

The Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) framework, which comprises domains on ‘implementation’ and ‘effectiveness’ and is suited to address challenges of blended effectiveness-implementation designs, guided the selection of implementation measures alongside Proctor et al taxonomy of implementation outcomes.

Participants
For M4M, 400 mothers (with their babies) will be randomised 2:1 to the intervention (N=270) versus control (N=130). Mothers over 18 years of age with symptoms of PND (defined as a diagnosis of major depressive disorder according to the Structured Clinical Interview for DSM-IV Disorders and a score of ≥10 on the EPDS) and a baby 0–9 months old, will be eligible. Mothers with an EPDS score of <10 will be excluded and signposted to other support services within the community (eg, mother–baby groups) but invited to re-screen for future cycles of the intervention (in case their symptoms change).

For PD-Ballet, 160 individuals will be recruited: 2:1 to the intervention (N=107) versus control (N=53). Participants will be 18 years old or over with a diagnosis of idiopathic PD according to the UK PD Brain Bank criteria and Hoehn Yarhr stages I–V. Individuals with a diagnosis of other Parkinsonism or an indication of dementia through a score of ≥21 on the Montreal Cognitive Assessment will be excluded.

Individuals (for both M4M/PD-Ballet) will also be excluded if they are unable to: understand English; give informed consent; access and attend the singing/dance sessions online (due to COVID-19) through an internet-connected device (eg, mobile phone, computer), or face-to-face (government guidelines permitting).

Individuals who decline participation or withdraw from M4M/PD-Ballet will be asked (providing they are willing) to provide their reason(s), so that barriers to uptake (from ‘decliners’) or continued participation (from ‘withdrawers’) can be identified and addressed.

SHAPER-Implement will also collect data on stakeholders’ attitudes and experiences of M4M/PD-Ballet (N=25–30, respectively) so that challenges relating to intervention delivery can be reviewed and overcome.

A description of power and sample size calculations for M4M/PD-Ballet can be found in the corresponding clinical protocols.

Patient and public involvement
We are engaging with members of the public and patients throughout SHAPER-Implement and at every stage of the research process. We have formed advisory groups comprising individuals who have already completed the PD-Ballet and M4M programme. To date, these individuals have provided feedback on (but not limited to) our study design, data collection measures, recruitment strategies and methods for disseminating findings.

Wider stakeholder engagement
In addition to patients/the public, engagement with other stakeholders is also critical to the success and scalability of M4M/PD-Ballet. We will hold regular meetings with: ‘deliverers’—artists/staff involved in delivering M4M/PD-Ballet; ‘referrers’—those who refer individuals to M4M/PD-Ballet (eg, general practitioners or neurologists (PD-Ballet); psychiatrists, health visitors and midwives (M4M) and; ‘supporters’—additional staff who support the running of M4M/PD-Ballet. To date, examples of involvement include contributing to the overall study design; critically reviewing methods of assessment for relevance and clarity; and exploring and facilitating referral pathways for recruitment.

Developing theory of change
We will conduct stakeholder workshops to develop theory of change (ToC) and logic models. The ToC element will focus on summarising M4M/PD-Ballet at a strategic level, capturing possible pathways for the change process to achieve our outcomes. The logic models will focus on the programme specifics, assessing the change process at the level of implementing M4M/PD-Ballet. We will advance the traditional logic model by drawing from the recently developed implementation research logic model. We will examine inputs (eg, time), activities (eg, recruitment), outputs (eg, publications), outcomes (eg, symptoms), implementation determinants (identified in the CFIR), implementation strategies, (drawing from the ERIC project) and mechanisms of action resulting from the implementation outcomes (informed by the implementation outcome taxonomy and RE-AIM).

Recruitment
Recruitment for M4M will be through: (1) signposting via health and social care professionals, including midwives and health visitors; (2) healthcare referrals, including general practitioners, clinical psychologists, psychiatrists and self-referral; (3) weighing clinics and other community and clinical centres for postnatal mothers; and: (4) social media groups and online forums aimed at new mothers (eg, of the consent form, refer to online supplementary file 1).

Recruitment for PD-Ballet will be through: (1) the Movement Disorders Outpatient Clinic at King’s College Hospital; (2) London South Parkinson’s Excellence Network (PEN) using the London South PEN patient section of the website; (3) London South and National Clinical Research Network websites and the EUROPAR website https://parkinsons-london.co.uk/europar/; (4) the Study Hub website (Parkinson’s UK) and; (5) the ENB.

Stakeholders will be recruited through Breathe’s (for M4M) and ENB’s (for PD-Ballet) network of artists, staff and others involved in M4M/PD-Ballet.
The start and end dates for the trials are September 2021–December 2023 (for M4M) and February 2022–December 2022 (for PD-Ballet). Follow-up data will be collected at 36 weeks so the full data collection for the trials will end in May 2024 (for M4M) and May 2023 (for PD-Ballet). It should be noted that more than one cycle of each programme will run for each trial, and that these cycles may overlap (ie, occur simultaneously) to varying degrees for M4M/PD-Ballet—hence, the slightly different durations of each of the trials.

**Measures**

Measures will be standardised across M4M/PD-Ballet, piloted and further refined (where applicable) through a codesign process with stakeholders to ensure their suitability.

Data on the acceptability of M4M/PD-Ballet (primary implementation outcome measure) and training in the delivery of M4M/PD-Ballet (SHAPER-Implement’s established implementation strategy), and data on the feasibility and appropriateness will be collected at three timepoints.

Implementation costs will be assessed using a previously developed costing proforma on the time and financial resource associated with implementing M4M/PD-Ballet within existing care pathways. To explore commissioning costs, feedback from provider organisations will be sought (those responsible for providing the interventions) to establish a range of plausible unit prices that the National Health Service (NHS)/partner organisations would be required to pay. To establish the impact of M4M/PD-Ballet on the wider utilisation of services (ie, other health and service costs), service utilisation questionnaires on the frequency of contact with other NHS/non-NHS services over a 3-month retrospective period will be completed. Reported service use will be costed using published unit cost estimates for healthcare and other services. The EQ5D 3L will be used to evaluate quality of life outcomes and quality-adjusted life year outcomes in the short-term.

To explore sustainment of M4M/PD-Ballet, the ‘Normalisation Measure Development’ questionnaire will be administered postintervention.

Enrolment onto M4M/PD-Ballet will assess uptake and participation data and attrition rates will be used to assess adherence.

Sociodemographic data on participants and stakeholders will be collected (see table 3 for further details on measures).

**Qualitative measures**

Semi-structured interviews partly informed by the study team’s methods of assessment for previous hybrid trials will complement the quantitative findings. Interviews will occur post-intervention and examine:

- Implementation strategies used to deliver M4M/PD-Ballet alongside strategies that may be important to consider by the local centres wishing to implement M4M/PD-Ballet after completion of SHAPER-Implement.
- Factors affecting the perceived acceptability, appropriateness and feasibility of M4M/PD-Ballet.
- Fidelity of delivery—whether M4M/PD-Ballet is delivered in accordance with protocol (eg, number and length of sessions, format and content covered).
- Fidelity of receipt—how the content of M4M/PD-Ballet is received by participants, including their experiences of engagement, comprehension of the content delivered, and application of acquired knowledge and skills to daily life.
- Factors affecting the sustained use of the knowledge and skills acquired from M4M/PD-Ballet for the long-term management of PND/PD (from participants) and the implementation of M4M/PD-Ballet into local services after the completion of SHAPER-Implement (from stakeholders).
- Unintended consequences (positive and negative) of M4M/PD-Ballet
- Stakeholders’ willingness for continued involvement in M4M/PD-Ballet (ie, intention to adopt) and participants’ intentions to use the knowledge and skills gained from M4M/PD-Ballet and recommend M4M/PD-Ballet to others.

**Data analysis**

**Quantitative implementation outcomes**

Parametric and non-parametric tests will be employed to compare survey responses between the two arms of the trial for M4M/PD-Ballet and the established implementation strategy (ie, training arts leads/ artists). Linear, logistic and Poisson regression models (depending on the distribution of the outcome) will explore the relationship between implementation (Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM)) and clinical trial primary (EPDS for M4M and MDS-MNS for PD-Ballet) and secondary outcome. Potential moderators (eg, age of the age of the baby for M4M) of the effect of implementation (AIM, IAM and FIM) on clinical trial primary (EPDS for M4M and MDS-MNS for PD-Ballet) and secondary outcome will be explored with the inclusion of an interaction term. Mediation analysis using structural equation models under the causal framework will be employed to understand the potential pathways in which implementation outcomes and the implementation strategy of ‘training’, impact on the effectiveness of M4M/PD-Ballet. All analyses will be conducted in STATA V.16.0.

**Psychometric assessment of the reliability, validity and factorial structure of the implementation survey scales**

The implementation outcomes scales are relatively new, hence require psychometric assessment. Cronbach’s coefficient alpha will evaluate the reliability...
(internal consistency) of the IAM, FIM and AIM scale-items (values range from 0 to 1 with internal consistency deemed acceptable when Cronbach’s alpha \( \geq 0.70 \)). A confirmatory factor analysis model will be fitted, using the weighted least square estimator with \( \chi^2 \) method to handle

---

### Table 3 Data collection plan for the implementation effectiveness evaluation of Melodies for Mums and PD-Ballet interventions

| Outcome                        | Definition                                                                                                                                                                                                 | Form of measurement          | Timepoint(s)                                                                 | Stakeholder group                      |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------------------------------------------|----------------------------------------|
| **Implementation effectiveness** |                                                                                                                                                                                                            |                              |                                                                            |                                        |
| Acceptability                  | Extent to which M4M/PD-Ballet are perceived to be agreeable and acceptable for management of PND and PD, respectively. Extent to which training in the delivery of M4M/PD-Ballet (ie, SHAPER-Implement’s established implementation strategy) is considered acceptable to arts leads/artists. | IAM survey interview         | During intervention, postintervention and 3–6 months postintervention follow-up | Participants and wider stakeholder groups |
| Appropriateness                | Extent to which M4M/PD-Ballet are perceived to be fit and relevant for management of PND and PD, respectively.                                                                                           | IAM survey interview         | During intervention, postintervention and 3–6 months postintervention follow-up | Participants and wider stakeholder groups |
| Feasibility                    | Extent to which M4M/PD-Ballet can be successfully used or carried out to help manage and improve PND and PD-related effects.                                                                                | FIM survey interview         | During intervention, postintervention and 3–6 months postintervention follow-up | Participants and wider stakeholder groups |
| Fidelity of delivery           | Extent to which M4M/PD-Ballet sessions were delivered according to protocol.                                                                                                                                   | Interview                    | Postintervention                                                           | Deliverers                             |
| Fidelity of receipt            | Extent to which M4M/PD-Ballet are received as intended.                                                                                                                                                       | Interview                    | Postintervention                                                           | Participants                            |
| Adoption                        | Intention to adopt and use the knowledge and skills learnt in M4M/PD-Ballet in everyday management of PND and PD.                                                                                        | Interview                    | Postintervention                                                           | Participants and wider stakeholder groups |
| Sustainability                  | Facilitators and barriers to sustained use of M4M/PD-Ballet.                                                                                                                                               | Interview and the NoMad survey | Postintervention and follow-up                                           | Participants and wider stakeholder groups |
| Uptake                          | The proportion and representativeness of individuals willing to participate in M4M/PD-Ballet.                                                                                                                   | Trial records, NoMad survey  | Baseline                                                                  | Provided by trial manager              |
| Adherence                       | The number of individuals attending each M4M/PD-Ballet session and the number of dropouts                                                                                                                   | Trial records                | Throughout intervention period                                              | Provided by trial manager              |
| Unintended consequences         | Positive or negative consequences that are not anticipated at the time of implementation of M4M/PD-Ballet.                                                                                                    | Interview                    | Postintervention                                                           | Participants and wider stakeholder groups |
| Implementation strategies*      | Strategies used to deliver and implement M4M/PD-Ballet.                                                                                                                                                     | Interview                    | Postintervention                                                           | Wider stakeholder groups               |
| **Implementation costs and cost effectiveness** |                                                                                                                                                                                                            |                              |                                                                            |                                        |
| Implementation costs            | Costs associated with prospective implementation of M4M/PD-Ballet.                                                                                                                                           | Costing proforma             | Postintervention                                                           | Participants and wider stakeholder groups |
| Cost-benefit analysis           | Costs associated with M4M/PD-Ballet vs the benefits in terms of the outcomes.                                                                                                                                   | EQ-5D 3L                    | During and postintervention                                                 | Participants                            |
| **Clinical effectiveness†**     | The impact of M4M/PD-Ballet on the clinical outcomes of interest.                                                                                                                                              | EPDS survey, NMSS survey     | Baseline, postintervention and 3–6 months postintervention follow-up       | Participants                            |

*As part of SHAPER-Implement we will be assessing the acceptability and benefit of ‘training arts leads/artists’ in the delivery of M4M/PD-Ballet (ie, our established implementation strategy) but we will also be examining other implementation strategies that may be of use in the wider-scale implementation of M4M/PD-Ballet.

†For further information on the clinical effectiveness evaluations, please refer to the corresponding clinical protocols for M4M\(^{31}\) and PD-Ballet\(^{32}\).

AIM, Acceptability of Intervention Measure; EPDS, Edinburgh Postnatal Depression Scale (Melodies for Murms); FIM, Feasibility of Intervention Measure; IAM, Intervention Appropriateness Measure; M4M, Melodies for Murms; NMSS, Non-Motor Symptoms Scale (Dance for Parkinson’s); NoMAD, Implementation measure based on Normalization Process Theory; PD, Parkinson’s disease; PD-Ballet, Dance for Parkinson’s; PND, postnatal depression; SHAPER, Scale-up of Health-Arts Programmes Effectiveness-Implementation Research.
ordered categorical items. To evaluate overall model fit, the comparative fit index (CFI), the Tucker Lewis index and the root mean square error of approximation (RMSEA) will be calculated. A CFI and TLI value of >0.90 indicates adequate fit to the data. A value of RMSEA <0.05 indicates close fit, values between 0.05 and 0.08 suggest adequate model fit, and values >0.10 suggest poor model fit. Psychometric analysis will be conducted using STATA V.16 and Mplus V.7.4.

Health economic outcomes

Using a combination of empirical and modelling methods, we will bring together evidence on clinical endpoints, quality-of-life, implementation and intervention costs, and epidemiological data on prevalence and service utilisation to gauge the cost-effectiveness of delivering M4M/PD-Ballet at scale. We will build in evidence-based assumptions regarding the long-term health and service resource impacts beyond the observable trial period. The cost-effectiveness of scalability under differing scenarios will be assessed with reference to existing thresholds, inclusive of those currently used by the National Institute for Health and Care Excellence for assessing programme cost-effectiveness. Uncertainty in estimates will be explored through probabilistic and one-way sensitivity analysis. Cost-effectiveness will be evaluated from an NHS perspective, with a focus on exploring the incidence of incremental resource impacts associated with utilisation of NHS funded resources.

Qualitative implementation outcomes

A systematic classification process of coding themes/patterns in the data will be used with the main themes predetermined deductively by the Proctor et al implementation outcomes framework and RE-AIM. Subthemes will be shaped inductively with the data until saturation is achieved. CFIR will be used to analyse barriers/facilitators (anticipated and actual) to the implementation and sustainment of M4M/PD-Ballet. NVivo V.12 will be used for data analysis.

ETHICS AND DISSEMINATION

M4M and PD-Ballet have been reviewed and approved by the West London and GTAC Research Ethics Committee (Reference: 20/PR/0813) and the HRA and Health and Care Research Wales Research Ethics Committee (Reference: 20/WA/0261). Informed consent will be sought from all research participants. The results will be disseminated in academic journals and conferences as well as other channels (including to patients and the public in the centres and healthcare settings where the programmes are being delivered and through social media).

Author affiliations
1Centre Implementation Science, King’s College London, London, UK
2Department of Psychological Medicine, King’s College London, London, UK
3Department of Behavioural Science and Health, University College London, London, UK
4Breathe Arts Health Research, London, UK
5South London and Maudsley NHS Foundation Trust, London, UK
6Faculty of Medicine, Imperial College London, London, UK
7Centre for Performance Science, Royal College of Music, London, UK
8Department of Basic and Clinical Neuroscience, King’s College London, London, UK
9English National Ballet, London, UK
10Department of Biostatistics and Health Informatics, King’s College London, London, UK

Twitter Carolina Estevao @carolinaestev and Manonmani Manoharan @csmony

Acknowledgements We would like to thank the representatives of the people with Parkinson’s disease and postnatal depression, as well as the artists and health care professionals involved, for their time and commitment to the design of this study protocol.

Contributors RED, TS, MBL, AH, CE, DF, PD, CP, HD, TO, RB, KS, LR, KH, AB, MM, RP, AP, RC, FD-F, AH, AW, NC, IB, NS (ie, all authors provided input on the design of the study and its conceptualisation), RD, TS, NS, AH, CE, IB and MLB were responsible for its drafting and edits. All authors provided feedback on all aspects of the content of the manuscript and its methodology. All authors read and approved the final version of the manuscript.

Funding This research was funded in whole, or in part, by the Wellcome Trust [219425/2/19/2]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. These trials included in SHAPER-Implement are part of the SHAPER programme, a Scaling-up Health-Arts Programme to scale up arts interventions, IB, AH and NS are funded by and RD is supported by the National Institute for Health Research (NIHR) via the ‘Applied Research Collaboration South London’ (NIHR ARC South London) at King’s College Hospital National Health Service (NHS) Foundation Trust, London, UK. AH and NS are members of King’s Improvement Science, which offers co-funding to the NIHR ARC South London and is funded by King’s Health Partners (Guy’s and St Thomas’ NHS Foundation Trust, King’s College Hospital NHS Foundation Trust, King’s College London and South London and Maudsley NHS Foundation Trust), and Guy’s and St Thomas’ Foundation. IB (is further funded) and CP are supported by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and CP is a NIHR Senior Investigator. MLB is further funded by Diabetes UK. RP is supported by HEAR5, a project funded by the UK’s Arts and Humanities Research Council to investigate the health, economic and social impact of the arts (Grant ref. AH/P005888/1). The funding agreements ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report. The views expressed are those of the authors and not necessarily reflect those of the NHS, the Wellcome Trust, the NIHR, the charities or the Department of Health and Social Care.

Competing interests NS is the Director of London Safety & Training Solution Ltd, which offers training in patient safety, implementation solutions and human factors to healthcare organisations and the pharmaceutical industry. TS received funding from Cancer Alliances and Health Education England for training multidisciplinary teams in assessment and quality improvement methods in the UK. TS received consultancy fees from Roche Diagnostics in relation to implementation of innovations for multidisciplinary teams and their meetings in the USA. DF is a non-executive board director for Breathe Arts Health Research. But she receives no financial compensation for her involvement. CP has received research funding from Johnson & Johnson for research on depression and inflammation, and by a Wellcome Trust strategy award to the Neuroneurology of Mood Disorders and Alzheimer’s Disease (NIMA) Consortium (104025), which is also funded by Janssen, GlaxoSmithKline, Lundbeck and Pfizer. The work presented in this paper is unrelated to this funding.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible.
REFERENCES
1. All-Party Parliamentary Group on Arts. Health and wellbeing inquiry report. creative health: the arts for health and wellbeing. All-Party Parliamentary Group on Arts, 2017.
2. Fancourt D, Finn S. What is the evidence on the role of the arts in improving health and well-being? A scoping review. who regional office for Europe, 2019.
3. Stuckey HL, Nobel J. The connection between art, healing, and public health: a review of current literature. Am J Public Health 2010;100:254–63.
4. Boyce M, Bungay H, Munn-Giddings C, et al. The impact of the arts in healthcare on patients and service users: a critical review. Health Soc Care Community 2018;26:459–73.
5. Eccles MP, Mitman BS. Welcome to implementation science. Implementation Sci 2006;1.
6. Estevao C, Fancourt D, Dazzan P, et al. Scaling-up Health-Arts programmes: the largest study in the world bringing arts-based mental health interventions into a national health service. BJPsych Bull 2021;45:32–9.
7. Boath E, Henshaw C. The treatment of postnatal depression: a comprehensive literature review. J Reprod Infant Psychol 2001;19:215–48.
8. McRell CJ, Warner R, Slade P, et al. Psychological interventions for postnatal depression: cluster randomised trial and economic evaluation. The ponder trial. Health Technol Assess 2009;13:1–153.
9. National Institute for Health Care Excellence. Parkinson’s disease in adults: National Institute for Health and Care Excellence, 2017.
10. UK Parkinson’s UK. Parkinson’s audit - Transforming care. UK Parkinson’s, 2017.
11. Bauer A, Parsaonge M, Knapp M. The costs of perinatal mental health problems. centre for mental health and London school of economics, 2014.
12. Parkinson’s UK. The cost of Parkinson’s: the financial impact of living with the condition. Parkinson’s UK, 2017.
13. Soundy A, Stubbs B, Roskell C. The experience of Parkinson’s disease: a systematic review and meta-ethnography. ScientificWorldJournal 2014;2014:1–19.
14. Yang W, Hamilton JL, Kopil C, et al. Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinsons Dis 2020;6:15.
15. Bledsoe SE, Grote NK. Treating depression during pregnancy and the postpartum: a preliminary meta-analysis. Res Soc Work Pract 2006;16:109–20.
16. Cooper PJ, Murray L, Wilson A, et al. Controlled trial of the short- and long-term effect of psychological treatment of postpartum depression. I. impact on maternal mood. Br J Psychiatry 2003;182:412–9.
17. Milgrom J, Negri LM, Gemmill AW, et al. A randomized controlled trial of psychological interventions for postnatal depression, Br J Clin Psychol 2005;44:529–42.
18. Cooper PJ, Murray L, Halligan SL. Treatment of postpartum depression. Winnicott Research Unit, University of Reading, UK: Centre of Excellence for Early Childhood Development, 2010.
19. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol 2012;2:1143–211.
20. Chaudhuri KR, Titova N, Department of Neurology, Neurosurgery and Medical Genetics, Pirogov Russian National Research Medical University, Moscow, Russian Federation. Societal burden and persisting unmet needs of Parkinson’s disease. Eur Neurol Rev 2019;14:28–35.
21. Martinez-Martín P, Rodriguez-Blasquez C, Kurits MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord 2011;26:399–406.
22. Bogner S, DeFaria AM, O’Dwyer C, et al. More than just dancing: experiences of people with Parkinson’s disease in a therapeutic dance program. Disabil Rehabil 2017;39:1073–8.
23. Fancourt D, Perkins R. Associations between singing to babies and symptoms of postnatal depression, wellbeing, self-esteem and mother-infant bond. Public Health 2016;145:149–52.
24. Fancourt D, Perkins R. Effect of singing interventions on symptoms of postnatal depression: three-arm randomised controlled trial. Br J Psychiatry 2018;212:119–21.
25. Fancourt D, Perkins R. The effects of mother–infant singing on emotional closeness, affect, anxiety, and stress hormones. Music Sci 2018;1:205920431774574.
26. Fancourt D, Perkins R. Creative interventions for symptoms of postnatal depression: a process evaluation of implementation. Arts Health 2019;11:38–53.
27. Houston S, McGill A. A mixed-methods study into ballet for people living with Parkinson’s. Arts Health 2013;5:103–19.
28. Cultural Commissioning Programme Case Study. English National Ballet Dance for Parkinson’s: Harnessing the power of dance to improve Health & Wellbeing, 2015.
29. Fancourt D, Perkins R. Does attending community music interventions lead to changes in wider musical behaviours? the effect of mother–infant singing classes on musical behaviours amongst mothers with symptoms of postnatal depression. Psychol Music 2019;47:132–43.
30. Perkins R, Yorke S, Fancourt D. How group singing facilitates recovery from the symptoms of postnatal depression: a comparative qualitative study. BMC Psychol 2018;6:41.
31. Estevao C, Binde R, Fancourt D, et al. SHAPER-PND trial: clinical effectiveness protocol of a community singing intervention for postnatal depression. BMJ Open 2021;11:e052333.
32. Podievwiska A, Davis R, Soukup T. Design of the PD-Ballet study: a randomised controlled single-blind hybrid type 2 clinical trial evaluating the effects of ballet dancing on motor and non-motor symptoms in Parkinson’s disease.
33. Curran GM, Bauer M, Mitman B, et al. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care 2012;50:217–26.
34. King’s Cultural Community. Arts, health & well-being: King’s College London. Available: https://www.kcl.ac.uk/cultural/arts-health-wellbeing/educuation.
35. King’s Cultural Community. Arts-enhanced health education. Available: https://www.kcl.ac.uk/cultural/arts-health-wellbeing/education.
36. Grigoriadis S, Wilton AS, Kurdysz PA, et al. Perinatal suicide in Ontario, Canada: a 15-year population-based study. CMAJ 2017;189:1085–92.
37. Sloman J, Horvo G, Emonts P, et al. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. Womens Health 2019;15:174506519844044.
38. Penalstein T, Howard M, Salisbury A, et al. Postpartum depression. Am J Obstet Gynecol 2009;200:357–64.
39. Alison C, Scott S. Pharmacologic and hormonal treatments for postpartum depression. Psychiatr Ann 2005;35:568–76.
40. Becki H. NHS England’s Access and Waiting Times Programme Perinatal Mental Health. 2015p. Available: http://www.swscn.org.uk/wp/wp-content/uploads/2015/12/07-31-presentation-NHS-perinatal-programme.pdf.
41. Yang G, Schmiel L, Zhou M. Economic Burden and Future Impact of Parkinson’s Disease Final Report. The Lewin Group, 2019.
42. Parkinson’s UK. The incidence and prevalence of Parkinson’s in the UK. Parkinson’s UK, 2018.
43. Kelberman MA, Vyaz EM. New pharmaceutical approaches to treating non-motor symptoms of Parkinson’s disease. Curr Pharm Rep 2016;2:253–61.
44. Zahoor I, Shafi A, Haq E. Pharmacological Treatment of Parkinson’s Disease. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Brisbane Codon Publications, 2018.
45. Barnish MS, Barran SM. A systematic review of active group-based dance, singing, music therapy and theatrical interventions for quality of life, functional communication, speech, motor function and cognitive status in people with Parkinson’s disease. BMC Neurol 2020;20:371.
46. McGill A, Houston S, Lee RYW. Effects of a ballet-based dance intervention on gait variability and balance confidence of people with Parkinson’s. Arts Health 2019;11:133–46.
47. Craig P, Dieppe P, Michet Y, et al. Developing and evaluating complex interventions: the new medical Research Council guidance. BMJ 2008;337:a1655.
48 Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new medical Research Council guidance. Int J Nurs Stud 2013;50:587–92.
49 Hull L, Gouding L, Khadjasian Z, et al. Designing high-quality implementation research: development, application, feasibility and preliminary evaluation of the implementation science research development (ImPro) tool and guide. Implement Sci 2019;14:80.
50 Soukup T, Hull L, Smith EL, et al. Effectiveness—implementation hybrid type 2 trial evaluating two psychoeducational programmes for severe hypoglycaemia in type 1 diabetes: implementation study protocol. BMJ Open 2019:9:303–70.
51 Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci 2011;6:42.
52 Consolidated framework for implementation research, 2021. Available: https://cfirguide.org/
53 Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci 2009;4:36.
54 Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation strategies: results from the expert recommendations for implementing change (ERIC) project. Implement Sci 2015;10:21.
55 Waltz TJ, Powell BJ, Matthieu MM, et al. Use of concept mapping to characterize relationships among implementation strategies and assess their feasibility and importance: results from the expert recommendations for implementing change (ERIC) study. Implement Sci 2015;10:109.
56 RE-ALM, 2021. Available: https://www.re-aim.org/
57 CRAWGE RB, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-ALM framework. Am J Public Health 1999;89:1322–7.
58 Smith JD, Li DH, Rafferty MR. The implementation research logic model: a method for planning, executing, reporting, and synthesizing implementation projects. Implement Sci 2020;15:84.
59 Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health 2011;38:65–76.
60 Weiner BJ, Lewis CC, Stanick C, et al. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci 2017;12:108.
61 Soukup THL, Smith EL, et al, PWD Group. The role, value and challenges of stakeholder involvement in implementation research. BMJ Q&S.
62 Soukup T, Hull L, Healey A. Interview topic guides exploring implementation outcomes across stakeholder groups (version 2) ZenoDo 2020.
63 Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36.
64 et alFinch TG, May M., Mair CR. NoMad: implementation measure based on normalization process theory, 2015. Available: http://www.normalizationprocess.org
65 Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. development of the 10-item Edinburgh postnatal depression scale. Br J Psychiatry 1987;150:782–6.
66 Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, et al. Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur J Neurol 2015;22:37–43.
67 De Stavola BL, Daniel RM, Ploubidis GB, et al. Mediation analysis with intermediate confounding: structural equation modeling viewed through the causal inference lens, Am J Epidemiol 2015;181:64–80.
68 RK. Principles and practice of structural equation modeling. 3rd ed. New York: Guilford press, 2011.
69 Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297–334.
70 DeVellis R. Scale development: theory and applications: SAGE publications, 2016.
71 Muthén B, du Toit S, Spisic D. Robust inference using weighted least squares and quadratic estimating equations in latent variable modeling with categorical and continuous outcomes. Psychometrika 1997;75:40–5.
72 Bentler PM. Comparative fit indexes in structural models. Psychol Bull 1990;107:238–46.
73 Tucker LR, Lewis C. A reliability coefficient for maximum likelihood factor analysis. Psychometrika 1973:38:1–10.
74 Steiger JH. Statistically-Based tests for the number of common factors, 1980.
75 Lt H, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Modeling 1999;6:1–55.
76 Muthén LK, Muthén BO. Mplus User’s Guide. 5th ed. Los Angeles, CA: Muthén & Muthén, 1998–2007.
77 Harden SM, Smith ML, Ory MG, et al. Re-aim in clinical, community, and corporate settings: perspectives, strategies, and recommendations to enhance public health impact. Front Public Health 2018;6:71.
78 Damschroder LJ, Hagedorn HJ. A guiding framework and approach for implementation research in substance use disorders treatment. PsycJob Addict Behav 2011;25:194–205.
79 Kirk MA, Kelley C, Yankey N, et al. A systematic review of the use of the consolidated framework for implementation research. Implement Sci 2011;16:72.
CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES

Please complete this form after you have read the Information Sheet and/or listened to an explanation about the research.

Title of Study: SHAPER-PND: Community singing interventions for postnatal depression: a hybrid type II effectiveness-implementation trial

Thank you for considering taking part in this research. One of the researchers from the research team will explain the project to you before you agree to take part. If you have any questions arising from the Information Sheet or explanation already given to you, please ask the researcher before you decide whether you should join in. You will be given a copy of this Consent Form to keep and refer to at any time.

Your information may be subject to review by responsible individuals from the research team for screening, monitoring and audit purposes.

Confidentiality will be maintained and you will not be identified in any research outputs.

I confirm that I understand that by ticking/initalling a ‘Yes’ box, I am consenting to being involved in this element of the study. I confirm that I understand that by ticking/initalling a ‘No’ box, I DO NOT consent to being involved in this element of the study.

1. I confirm that I have read and understood the information sheet dated [30-Jul-2021, version 2.1] for the above study. I have had the opportunity to consider the information and asked questions which have been answered to my satisfaction.

2. I consent voluntarily for myself and for my baby to be a participant in this study and understand that I can withdraw from the study at any time, without having to give a reason.

3. I consent to the processing of my personal information for the purposes explained to me in the Information Sheet. I understand that such information will be handled confidentially, in accordance with the terms of the General Data Protection Regulation.

4. I agree that the research team may use my data for future research within and outside the EU and understand that any such use of identifiable data would be reviewed and approved by a research ethics committee. In such cases, as with this project, data will not be identifiable in any report.

5. I agree to be contacted in the future by King’s College London researchers who would like to invite me to participate in follow up studies to this project, or in future studies of a similar nature.

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on the information supplied by the author(s). BMJ Open is an exclusively online journal published by BMJ Publishing Group Limited on behalf of the BMJ Publishing Group, an independent organisation with no commercial interest in the journal. BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on the content of this supplement or on any of the related materials hosted on any other server and does not accept any legal responsibility or liability for any such reliance. Supplemental material has been supplied by the author(s). doi: 10.1136/bmjopen-2021-055691
6. I agree to provide details of my GP and understand that if any safeguarding issues arise, my GP might be contacted to discuss the best way to support me and my baby. 

7. I agree to record short videos being taken of play interaction in a comfortable setting between my baby and me. This recording aims to look at how me and my baby interact with each other and the information obtained can be used for our research.

8. I agree to my views being shared in focus groups and subsequent interviews to be recorded (in audio and/or video format) for data collection. The researchers may use a transcription service to transcribe the recordings into a different format. I understand that my identity will stay anonymous and I will not be identifiable in the published data or materials. (optional)

9. I agree to provide biological samples (saliva) throughout the study in accordance to the study protocol. (optional)

10. I agree to provide biological samples (hair) throughout the study in accordance to the study protocol. (optional)

11. My biological samples may be used for future studies and my data will remain anonymous. (optional)

12. I agree to provide biological samples (saliva only) of my baby in accordance to the study protocol. (optional)

13. The biological samples of my baby may be used for future studies and the data will remain anonymous. (optional)

14. I agree to be contacted by implementation science researchers to provide my views on the study. I understand that my views may be video and audio recorded and published but I will not be identifiable in any of the research outputs. (optional)

15. I do not wish to participate in the study, but I agree to be contacted by implementation science researchers for a brief interview, to explain why. (optional)

Note that you must consent to points 1-7 in order to be eligible for the study. Points 8-14 are not mandatory but are still an integral part of the study. If you do not wish to participate in the study but consent to being contacted to tell us why (optional), just tick point 15.

Participant:

Your Name __________________________  Date __________________________  Signature __________________________

Researcher:

Name of Researcher __________________________  Date __________________________  Signature __________________________